Elektrofi, a Boston-based biotechnology company focused on drug formulation and delivery innovations, has entered into a collaboration and license agreement with argenx to explore new subcutaneous formulations for therapeutic products directed at the human neonatal Fc receptor (FcRn), including efgartigimod, and up to one additional target. The Elektrofi-enabled formulations are aimed to promote additional optionality for patients through at-home and self-administration capabilities.   Unde...